CB-03-01
Shop CB-03-01 on KimeraChems · code GUIDE (10% off)Definition
CB-03-01 (clascoterone, CAS 19608-29-8) is a laboratory-grade synthetic steroidal antiandrogen characterized by localized androgen receptor antagonism with rapid metabolic inactivation, making it suitable for tissue-selective androgen signaling research rather than systemic hormone suppression studies. In research settings it is investigated for peripheral androgen receptor blockade, androgen-responsive gene modulation, and skin- and follicle-focused hormone signaling models. CB-03-01 from Kimera is supplied as a liquid research material at 50 mg/mL in a mixed solvent system and is explicitly not approved for human or veterinary use.
Available Formats
- 150 mg solution (50 mg/mL; 30 mL total volume)
Mechanism of Action
Research characterizes CB-03-01 as a steroidal androgen receptor antagonist with work focusing on: The compound’s primary value lies in controlled dissection of androgen receptor pharmacology and localized hormone signaling rather than any clinical or consumer application.
- Competitively inhibiting androgen binding at the androgen receptor in peripheral tissues (e.g., skin and follicles).
- Reducing androgen-responsive gene transcription in cellular and tissue models exposed to androgens.
- Leveraging rapid hydrolysis into inactive metabolites to limit systemic androgen suppression and maintain a localized activity profile.
- Exploring tissue-selective hormone modulation and receptor blockade in comparison to systemic antiandrogens in preclinical models.
Areas of Investigation
CB-03-01 is commonly used in research for
- Androgen receptor signaling studies, including receptor binding and antagonism in peripheral tissues.
- Skin and follicular biology research, with emphasis on androgen-driven pathways in dermatological models.
- Localized hormone modulation models designed to minimize systemic endocrine disruption.
- Comparative antiandrogen analysis against other steroidal and nonsteroidal androgen receptor modulators.
- Structure–activity relationship (SAR) projects involving steroidal antiandrogen scaffolds and cortexolone-derived analogs.
Safety Profile
No standardized toxicity profile for CB-03-01 is established in public-facing RUO materials from Kimera. The compound is treated as a laboratory chemical that requires appropriate personal protective equipment, controlled handling, and storage under cool, dry, light‑protected conditions to maintain stability. Any hazard assessment must follow institutional protocols for steroidal small‑molecule research chemicals and applicable regulatory standards.
Interaction Notes
- Utilized conceptually alongside other androgen receptor ligands and hormone modulators in comparative pharmacology and SAR frameworks.
- Positioned as a tool compound for dissecting androgen receptor signaling and tissue‑selective hormone modulation rather than for combination “therapies.”
- No consumer‑level interaction data or clinical drug‑interaction profiles are documented, as it is not intended for therapeutic use.
For educational purposes only. Not for human consumption.